Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-527 and Rosuvastatin Interaction Study
NCT05154123Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19) and hepatitis C (HCV) (2 arms), sponsored by Atea Pharmaceuticals. Primary endpoints: Pharmacokinetics of rosuvastatin (Effect of AT-527 co-administration) at Day 8 and Pharmacokinetics of rosuvastatin (Effect of staggered AT-527) at Day 8. Started Nov 2021; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05154123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05154123.